首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Drug Resistance Updates

Drug Resistance Updates杂志,由Churchill Livingstone出版,于1998年创刊,Bimonthly,出版语言English,ISSN:1368-7646,E-ISSN:1532-2084。

投稿咨询
Drug Resistance Updates
Drug Resistance Updates
Drug Resistance Updates
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
22
CiteScore
29.1
期刊收录
SCI、SCIE

Drug Resistance Updates(中文译名:《耐药性更新》),ISSN:1368-7646,EISSN:1532-2084,是Churchill Livingstone出版的国际性学术期刊,创刊于1998年,以Bimonthly形式稳定发行,2026年总发文量约93篇。该刊采用混合开放访问,学科归属为医学 - 药学。该刊是医学、药学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达22,2025年期刊CiteScore为29.1,2025年期刊自引率约3.2%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Drug Resistance Updates长期聚焦医学、药学及相关产业的技术应用前沿,平均审稿周期约稿?周期不定,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、药学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,IsraelItaly、USA、Netherlands、GERMANY (FED REP GER)、CHINA MAINLAND、Portugal等为核心发文国家与地区;TECHNION ISRAEL INSTITUTE OF TECHNOLOGYUNIVERSITY OF AMSTERDAM、INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)、SAINT JOHN'S UNIVERSITY、VRIJE UNIVERSITEIT AMSTERDAM、IRCCS AVIANO (CRO)、RUDJER BOSKOVIC INSTITUTE等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
PHARMACOLOGY & PHARMACY 药学
1区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
PHARMACOLOGY & PHARMACY 药学
1区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
PHARMACOLOGY & PHARMACY 药学
1区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q1 3 / 356

99.3

学科:PHARMACOLOGY & PHARMACY SCIE Q1 2 / 356

99.58

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q1 2 / 352

99.6

学科:PHARMACOLOGY & PHARMACY SCIE Q1 2 / 353

99.58


中国学者近期发文

1
Interferon regulatory factor 5 associated neutrophil reprogramming by trained immunity protects against lethal-dose bacterial sepsi

Author:Li, Liyuan; Liu, Chibo; Zhang, Mingming; Gou, Yawei; Zhang, Xinfang; Qi, Yan; Liu, Lingling; Wang, Renhao; Jiang, Jiashan; Wang, Ruonan; Wang, Shengnan; Shan, Wenbo; Zhao, Xi; Li, Haokun; Wang, Zhenbo; Li, Jing; Sun, Wei

Journal: DRUG RESISTANCE UPDATES. 2026; Vol. 87, Issue , pp. -. DOI: 10.1016/j.drup.2026.101393

2
Nanoparticle-based immunotherapeutic strategies to overcome cancer drug resistance: From biological barriers to artificial intelligence-driven desig

Author:Kong, Xiangyi; Cheng, Ran; Zhang, Wenxiang; Lu, Ye; Kan, Yonemori; Fang, Yi; Gao, Jidong; Wang, Jing; Hwang, Kuo Chu

Journal: DRUG RESISTANCE UPDATES. 2026; Vol. 86, Issue , pp. -. DOI: 10.1016/j.drup.2026.101392

3
Mechanisms of therapy resistance in the tumor microenvironment: Insights from antibody array-based cytokine profilin

Author:Wickramasekara, Rochelle; Jones, Valerie; Zhao, Yating; Luo, Shuhong; Sun, Guogui; Huang, Ruo-Pan

Journal: DRUG RESISTANCE UPDATES. 2026; Vol. 86, Issue , pp. -. DOI: 10.1016/j.drup.2026.101378

4
Stabilin-1 +lipid-associated macrophages promote lung adenocarcinoma liver metastasis and osimertinib resistance through impairing macrophage phagocytosis via SIRPα-CD47 axi

Author:Wang, Qi; Zhou, Jiuli; Li, Xuefei; Zhao, Chao; Cheng, Lei; Wang, Li; Chen, Jianing; Chen, Chang; Li, Chunyu; Su, Chunxia

Journal: DRUG RESISTANCE UPDATES. 2026; Vol. 86, Issue , pp. -. DOI: 10.1016/j.drup.2026.101379

5
Recent advances in near-infrared fluorescent ligands as a novel frontier in combating antibiotic-resistant bacteri

Author:Zheng, Wen-De; Zeng, Yao-Xun; Chen, Ze-Xin; Dong, Jia-Peng; Zheng, Ying-Ying; Wong, Wing-Leung

Journal: DRUG RESISTANCE UPDATES. 2026; Vol. 86, Issue , pp. -. DOI: 10.1016/j.drup.2026.101382

6
ATP-binding cassette subfamily A member 5 suppresses pancreatic ductal adenocarcinoma progression and chemoresistance by promoting (3-catenin ubiquitin-dependent degradatio

Author:Li, Zhenchong; Ma, Zuyi; Chen, Yubin; Yu, Weixuan; Yu, Jiajie; Lu, Jianmin; Zhang, Qiaoling; Wu, Qianlong; Cai, Yifeng; Wang, Zeyao; Shang, Changzhen; Hou, Baohua; Zhang, Chuanzhao; Huang, Shanzhou; Wang, Linhe; Zhou, Qi

Journal: DRUG RESISTANCE UPDATES. 2026; Vol. 86, Issue , pp. -. DOI: 10.1016/j.drup.2026.101381

7
Emerging trends and converging evidence in tumor evolution: A comprehensive revie

Author:Jin, Chenqi; Li, Weiqi; Liu, Boqiang; Cao, Lu-Qi; Stefan, Sven Marcel; Yuan, Luoxi; Yu, Xin; Shi, Liang; Yu, Hong

Journal: DRUG RESISTANCE UPDATES. 2026; Vol. 86, Issue , pp. -. DOI: 10.1016/j.drup.2026.101380

8
Combination of PD-1 blockade and neoadjuvant chemoradiotherapy benefits pMMR/MSS patients with locally advance rectal cancer: A phase 2 clinical tria

Author:Yang, Zhengyang; Xu, Zhuan; Sun, Liting; Zheng, Jianyong; Han, Jiagang; Li, Ang; Liu, Gang; Sun, Yi; Zhang, Jie; Chen, Guangyong; Xu, Rui; Zhang, Chao; Gao, Jiale; Bai, Zhigang; Deng, Wei; Yao, Hongwei; Zhang, Zhongtao

Journal: DRUG RESISTANCE UPDATES. 2026; Vol. 86, Issue , pp. -. DOI: 10.1016/j.drup.2026.101384

9
Programmed cell death network in cancer drug resistance: A framework for therapeutic interventio

Author:Guo, Dezhi; Guo, Yadong; Zhu, Chenglong; Liao, Yan; Lin, Zhiheng; Zhang, Haoling; Zhang, Wangzheqi; Zou, Zui

Journal: DRUG RESISTANCE UPDATES. 2026; Vol. 86, Issue , pp. -. DOI: 10.1016/j.drup.2026.101387

10
Oridonin derivative DLC13 targeting proliferating cell nuclear antigen to overcome oxaliplatin resistance in colorectal cancer?

Author:Wang, Shuping; Li, Jipin; Chen, Yali; Gao, Tian; Yong, Tao; Zeng, Tingyu; An, Yu; Yang, Dong-Hua; Chen, Zhe-Sheng; Xu, Jinyi; Shi, Lei; Li, Dahong; Xu, Shengtao

Journal: DRUG RESISTANCE UPDATES. 2026; Vol. 86, Issue , pp. -. DOI: 10.1016/j.drup.2026.101390


在线咨询

Drug Resistance Updates

国际简称:DRUG RESIST UPDATE参考译名:耐药性更新

年发文量:93 CiteScore:29.1 是否预警:否 Gold OA文章占比:35.71% 研究类文章占比:100.00%

杂志社联系方式:CHURCHILL LIVINGSTONE, JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH, SCOTLAND, MIDLOTHIAN, EH1 3AF

Drug Resistance Updates